157 related articles for article (PubMed ID: 11148683)
21. [New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics].
Bover J; Ballarín J; Andrés E; Ortiz-Herbener F; Barceló P
Nefrologia; 2005; 25 Suppl 2():109-16. PubMed ID: 16050413
[TBL] [Abstract][Full Text] [Related]
22. [Osteoporosis and other bone diseases in elderly patients].
Matsumoto T
Nihon Naika Gakkai Zasshi; 2004 Dec; 93(12):2572-8. PubMed ID: 15658487
[No Abstract] [Full Text] [Related]
23. Parathyromatosis and the challenge of treatment.
Daphnis E; Stylianou K; Katsipi I; Stratigis S; Karamitopoulou E; Karkavitsas N; Kyriazis J
Am J Kidney Dis; 2006 Sep; 48(3):502-5. PubMed ID: 16931226
[TBL] [Abstract][Full Text] [Related]
24. Cinacalcet for the treatment of primary hyperparathyroidism.
Dillon ML; Frazee LA
Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
[TBL] [Abstract][Full Text] [Related]
25. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
[TBL] [Abstract][Full Text] [Related]
26. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
[TBL] [Abstract][Full Text] [Related]
27. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent.
Collins MT; Skarulis MC; Bilezikian JP; Silverberg SJ; Spiegel AM; Marx SJ
J Clin Endocrinol Metab; 1998 Apr; 83(4):1083-8. PubMed ID: 9543122
[TBL] [Abstract][Full Text] [Related]
28. Cinacalcet hydrochloride: calcimimetic for the treatment of hyperparathyroidism.
Locatelli F; Pontoriero G; Limardo M; Tentori F
Expert Rev Endocrinol Metab; 2006 Mar; 1(2):167-179. PubMed ID: 30754140
[TBL] [Abstract][Full Text] [Related]
29. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
[TBL] [Abstract][Full Text] [Related]
30. [Progress in diagnosis and therapy: Hypercalcemia due to primary hyperparathyroidism].
Sugimoto T
Nihon Naika Gakkai Zasshi; 2007 Apr; 96(4):662-8. PubMed ID: 17506301
[No Abstract] [Full Text] [Related]
31. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
32. The calcium receptor and calcimimetics.
Wada M; Nagano N; Nemeth EF
Curr Opin Nephrol Hypertens; 1999 Jul; 8(4):429-33. PubMed ID: 10491737
[TBL] [Abstract][Full Text] [Related]
33. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery.
Räkel A; Brossard JH; Patenaude JV; Albert C; Nassif E; Cantor T; Rousseau L; D'Amour P
Clin Endocrinol (Oxf); 2005 Jun; 62(6):721-7. PubMed ID: 15943835
[TBL] [Abstract][Full Text] [Related]
34. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
[TBL] [Abstract][Full Text] [Related]
35. [Parathyroid gland, calcium receptor and calcimimetics].
Ureña P
Nephrologie; 2002; 23(4):151-64. PubMed ID: 12125321
[TBL] [Abstract][Full Text] [Related]
36. Skeletal effects of primary hyperparathyroidism.
Syed Z; Khan A
Endocr Pract; 2000; 6(5):385-8. PubMed ID: 11141591
[TBL] [Abstract][Full Text] [Related]
37. Hyperparathyroidism.
Fraser WD
Lancet; 2009 Jul; 374(9684):145-58. PubMed ID: 19595349
[TBL] [Abstract][Full Text] [Related]
38. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
39. Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism.
van der Plas WY; Engelsman AF; Özyilmaz A; van der Horst-Schrivers AN; Meijer K; van Dam GM; Pol RA; de Borst MH; Kruijff S
Ann Surg Oncol; 2017 Jan; 24(1):15-22. PubMed ID: 27459979
[TBL] [Abstract][Full Text] [Related]
40. Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism.
Jansson S; Morgan E
World J Surg; 2004 Dec; 28(12):1293-7. PubMed ID: 15517486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
